CpG oligodeoxynucleotide 1826 enhances the lewis lung cancer response to radiotherapy in murine tumor

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 2, 2011, Pages 203-208

  Yuan, Sujuan ^a   Qiao, Tiankui ^a   Chen, Wei ^a  

^a JINSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

apoptosis; Lewis lung cancer; oligodeoxyribonucleotides; sensitization enhancement ratio; tumor growth delay

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; LUNG CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOSENSITIVITY; TUMOR GROWTH; X RAY;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; CARCINOMA, LEWIS LUNG; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; INTERLEUKIN-10; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; RADIATION ONCOLOGY; RADIATION TOLERANCE; SPLEEN; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA; X-RAYS;

EID: 79955926724     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0871     Document Type: Article

References (23)

1. Wang H, Rayburn ER, Wang W, et al. Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting toll-like receptor 9. Mol Cancer Ther 2006;5:1585.
2. Jahrsdö rfer B, Weiner GJ. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 2008;3:27.
3. Yron I, Weiss DW, Robinson E, et al. Immunotherapeutic studies in mice with the methanol-extraction residue (mer) fraction of BCG: Solid tumors. Natl Cancer Inst Monogr 1973;39:33.
4. Mason KA, Ariga H, Neal R, et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 2005;11:361.
5. Tokunaga T, Yamamoto T, Yamamoto S. How BCG led to the discovery of immunostimulatory DNA. Jpn J Infect Dis 1999;52:1.
6. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546.
7. Mason KA, Neal R, Hunter N, et al. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. Radiother Oncol 2006;80:192.
8. Saha A, Bhattacharya-Chatterjee M, Foon KA, et al. Stimulatory effects of CpG oligodeoxynucleotide on dendritic cellbased immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice. Int J Cancer 2008;124:877.
9. Akira S, Takeda K, Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675.
10. Kawarada Y, Ganss R, Garbi N, et al. NK- and CD8(1) T cellmediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001;167:5247.
11. Baines J, Celis E. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res 2003;9:2693.
12. Payton LA, Lewis JD, Byrne JA, et al. Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity. Cancer Immunol Immunother 2008;57:799.
13. Heckelsmiller K, Beck S, Rall K, et al. Combined dendritic cell- and CpGoligonucleotide-based immune therapy cureslarge murine tumors that resist chemotherapy. Eur J Immunol 2002;32:3235.
14. Meng Y, Carpentier AF, Chen L, et al. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer 2005;116:992.
15. Tsujie M, Tsujie T, Toi H, et al. Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent micent. J Cancer 2008;122:2266.
16. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004;6:88.
17. Weigel BJ, Rodeberg DA, Krieg AM, et al. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003;9:3105.
18. Milas L, Mason KA, Ariga H, et al. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 2004;64:5074.
19. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117:1184.
20. Sparsser T, Miethke T, Liporford, et al. Bacterial DNA causes septic shock. Nature 1998;386:336.
21. Jahrsdö rfer B, Wooldridge JE, Blackwell SE, et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 2005;77:378.
22. El Andaloussi A, Sonabend AM, Han Y, et al. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006;54:526.
23. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8:1765.